Innovative Bispecific Nanobody Targeting CD276 and EGFR for Next-Generation Cancer Therapy

VHH-P414 is a bispecific, humanized nanobody therapeutic candidate designed to target both the CD276 molecule (CD276) and the epidermal growth factor receptor (EGFR). Utilizing advanced protein engineering, this molecule fuses a single-domain antibody targeting CD276 to the N-terminus of an anti-EGFR single-chain variable fragment. Expressed in Chinese hamster ovary cells, VHH-P414 is currently in the Biological Testing stage, with promising potential for cancer treatment by addressing two critical tumor-associated targets. This dual-targeting approach offers novel opportunities for enhanced anti-tumor activity across a broad range of malignancies.

Licensing Opportunity

VHH-P414 is currently available for out-licensing and strategic partnerships. We welcome inquiries from collaborators and industry partners to advance its development toward clinical and commercial success.

Development Phase

Modality

VHH-P414 employs an innovative bispecific modality, integrating a humanized single-domain antibody (nanobody) with specificity for CD276 and an anti-EGFR single-chain variable fragment, genetically fused at the molecular level. The nanobody format confers multiple advantages, including reduced molecular size for improved tumor penetration, enhanced tissue distribution, and intrinsic stability compared to traditional antibody formats. Expression in Chinese hamster ovary cells facilitates scalable production. The bispecific structure enables simultaneous engagement of CD276 and EGFR, two validated oncology targets, which may result in superior efficacy and more comprehensive cancer cell targeting than monospecific biologics.

Target

CD276 and EGFR are both pivotal cell surface proteins implicated in cancer. CD276, a member of the B7 family, is widely overexpressed across numerous tumor types and is associated with tumor immune evasion and poor patient outcomes. EGFR is a well-characterized receptor tyrosine kinase that regulates cell proliferation, survival, and differentiation and is frequently upregulated or mutated in several solid malignancies. CD276 and EGFR are minimally present in normal tissues but highly expressed on tumor cells and tumor-associated vasculature, making them attractive therapeutic targets. Targeting CD276 and EGFR concurrently with VHH-P414 may disrupt tumor signaling and immune evasion, providing strategic benefit and differentiation in oncology drug development.

Mechanism of Action

VHH-P414 exerts its therapeutic effect through dual mechanisms by selectively binding to CD276 and EGFR on cancer cells. Engagement of CD276 inhibits this immune checkpoint, potentially restoring anti-tumor immune responses and countering immune suppression within the tumor microenvironment. Simultaneous targeting of EGFR interferes with oncogenic signaling pathways, inhibiting tumor cell growth, proliferation, and survival. As an immune checkpoint inhibitor and a signal transduction modulator, VHH-P414 offers the promise of synergistic anti-cancer effects. The nanobody-based platform of VHH-P414 also provides opportunities for future derivatization, such as the development of next-generation bispecifics, multispecifics, or antibody-drug conjugates to further enhance clinical utility.

Cancer

Cancer represents a group of diseases characterized by uncontrolled cellular proliferation, invasion into surrounding tissues, and potential for metastasis. As a leading cause of morbidity and mortality worldwide, cancer encompasses a wide spectrum of solid and hematologic malignancies affecting millions of patients. Current mainstays of therapy include surgery, radiation, chemotherapy, targeted agents, and immunotherapies. While recent advances have improved outcomes, substantial challenges remain: many cancers develop resistance to existing treatments, and toxicities limit the effectiveness of conventional regimens. There is a pressing need for novel therapeutics that address both tumor growth and immune evasion. By specifically targeting both CD276 and EGFR—molecules involved in immune suppression and tumor progression—VHH-P414 is positioned to address unmet clinical needs. Its innovative bispecific nanobody design holds promise for improving the depth and durability of anti-cancer responses across diverse patient populations.